Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.NewCardio has received a certificate of grant from the European Patent Office covering CardioBip, its proprietary device and methodology for transtelephonic transmission of comprehensive ECG data.
Subscribe to our email newsletter
The patent application was submitted under the patent cooperation treaty with 33 claims covering the device, related systems and methods of use. All 33 claims were allowed by the European Patent Office on its first office action. The same application is currently being reviewed in the US, China, Japan, and Korea and the company is awaiting first office actions from these countries.
The CardioBip is a unique, hand-held device that provides a solution to the problem of urgent ECG telemonitoring. The CardioBip is capable of providing truly comprehensive and accurate ECG data that can be transmitted wirelessly. The CardioBip works without any cables and the device’s electrodes are integrated, offering a potential for integration with hand-held PDA platforms.
Branislav Vajdic, CEO of NewCardio, said: “We believe the CardioBip technology has an important role to play in detection and monitoring of potentially fatal cardiac diseases. NewCardio is committed to advancing the widely accepted 12-lead ECG to deliver innovation to the cardiac sciences.”